Statements (55)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:Company
|
| gptkbp:acquired |
Nexavar rights in India
|
| gptkbp:appears_in |
the European market
the Indian market the Indian pharmaceutical market the US market |
| gptkbp:collaborated_with |
academic institutions
|
| gptkbp:cultural_representation |
therapeutic products
|
| gptkbp:depicted_in |
gptkb:BSE
NSE |
| gptkbp:develops |
new drug formulations
|
| gptkbp:employs |
over 10,000 people
|
| gptkbp:flows_into |
new drug candidates
|
| gptkbp:focuses_on |
generic drugs
biologics affordable healthcare solutions branded drugs therapeutic areas like cardiovascular diseases therapeutic areas like diabetes therapeutic areas like infectious diseases therapeutic areas like neurology therapeutic areas like pain management |
| gptkbp:founded |
gptkb:1977
|
| gptkbp:founder |
gptkb:Glenmark_Pharmaceuticals
|
| gptkbp:headquartered_in |
gptkb:Maharashtra
|
| gptkbp:headquarters |
gptkb:Mumbai
|
| https://www.w3.org/2000/01/rdf-schema#label |
Glenmark
|
| gptkbp:is_committed_to |
sustainability
corporate social responsibility patient access programs |
| gptkbp:is_involved_in |
clinical trials
global health initiatives vaccine development |
| gptkbp:is_known_for |
its respiratory products
its commitment to research and development its dermatology products its oncology products |
| gptkbp:is_recognized_by |
a leading player in the pharmaceutical industry.
|
| gptkbp:is_recognized_for |
its contributions to healthcare
|
| gptkbp:members |
various industry associations
|
| gptkbp:operates_in |
over 80 countries
|
| gptkbp:partnerships |
various global pharmaceutical companies
|
| gptkbp:produced_by |
active pharmaceutical ingredients
finished dosage forms |
| gptkbp:received |
numerous awards for innovation
multiple FDA approvals |
| gptkbp:research_areas |
gptkb:Mumbai
gptkb:Baroda Baddi |
| gptkbp:subsidiary |
gptkb:Africa
gptkb:Europe gptkb:Latin_America gptkb:the_United_States |
| gptkbp:bfsParent |
gptkb:Anders_Glenmark
|
| gptkbp:bfsLayer |
4
|